Smithbridge Asset Management Inc. DE Sells 100,198 Shares of Novo Nordisk A/S $NVO

Smithbridge Asset Management Inc. DE cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 50.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,990 shares of the company’s stock after selling 100,198 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Novo Nordisk A/S were worth $3,638,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NVO. Franklin Resources Inc. boosted its stake in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares during the period. Capital International Investors increased its stake in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $310,199,000. Price T Rowe Associates Inc. MD raised its holdings in Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after acquiring an additional 4,836,285 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 851.6% during the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after acquiring an additional 4,302,126 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, March 10th. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Five equities research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $48.69 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $71.79. The stock has a market capitalization of $217.40 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 4.33 and a beta of 0.77. The stock has a fifty day moving average of $44.25 and a 200-day moving average of $45.81.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Medicare is starting temporary coverage for GLP-1 obesity treatments, including Novo Nordisk’s Wegovy injection and tablet, which could broaden access and increase demand for the company’s weight-loss drugs. Medicare will start covering obesity drugs for the first time. Here’s what patients should know
• Positive Sentiment: Shantha Biologics announced an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India, a move that could help strengthen supply and support future product demand. Shantha Biologics Announces Cartridge Fill-Finish Collaboration
• Positive Sentiment: Nordea upgraded Novo Nordisk to Buy, signaling improved analyst confidence in the stock’s valuation and dividend appeal. Novo Nordisk (NVO) Upgraded to Buy at Nordea. Here is Why
• Positive Sentiment: Shares also rose after the company was highlighted as outperforming the broader market in recent trading, reflecting investor appetite for the name amid obesity-drug optimism. Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: News coverage around weight-loss ETFs and broader obesity-treatment investing reinforces sector interest, but it is more of a thematic tailwind than a direct catalyst for Novo Nordisk. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS estimate slightly, which is a modest cautionary note, though it did not change the broader longer-term growth story. Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.